68 results
8-K
EX-99.1
NTBL
Notable Labs Ltd
8 Apr 24
Other Events
12:15pm
at AACR 2024. The ability to derive a high-quality assessment of the response to treatment based on the results of cryopreserved samples is an important
8-K
EX-99.1
NTBL
Notable Labs Ltd
22 Feb 24
Other Events
8:15am
are i) a positive predicted response rate and ii) a per-protocol response assessment of complete remission and overall survival.
The Phase 2 program
DEF 14A
NTBL
Notable Labs Ltd
16 Feb 24
Definitive proxy
9:00am
by the Compensation Committee and the Board, based on quantitative and qualitative criteria.
Beginning for calendar year 2024, an assessment of Dr … . The actual bonus to be paid (if any) will be determined based on the foregoing assessment of Dr. Bock’s achievement of the objectives for the year
PRE 14A
aceju8t143qm 9fwkbjp
5 Feb 24
Preliminary proxy
5:00pm
8-K
EX-99.1
ufzri1qbjrv1
18 Dec 23
Other Events
8:15am
8-K/A
EX-99.2
n3x3zyj
29 Nov 23
Financial Statements and Exhibits
5:00pm
424B3
ksgcyuvg79dy
5 Sep 23
Prospectus supplement
6:02pm
S-4/A
px7g t0yfeq
30 Jun 23
Registration of securities issued in business combination transactions (amended)
4:38pm
S-4
r5e4re
11 May 23
Registration of securities issued in business combination transactions
9:09am
6-K
EX-1.1
ine6t0yas31paysqek
11 Feb 22
Current report (foreign)
5:29pm
424B5
749g6whh
11 Feb 22
Prospectus supplement for primary offering
5:28pm
6-K
EX-99.2
fwk3w8z149u81uzf
15 Nov 21
VBL Therapeutics Reports Third Quarter 2021 Financial Results
7:00am
6-K
blqwt8z2r 3nlp
16 Aug 21
Current report (foreign)
7:00am